But in findings presented at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Orlando, the novel ...
LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety ...
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership ...
FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...
There was an increase in the hepatic fat fraction, the long-term consequences of which are unknown, says Robert Rosenson.
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) ...
The company plans to initiate two registrational studies for NDV-01 and a Phase II sepranolone study in the first half of 2026. Traversa also spotlighted the hiring of Dr. Raj Pruthi as Chief Medical ...
Carol Saffran started taking Ozempic a year ago to regulate her blood sugar after other medications were ineffective. She was ...
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.
Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q3, 2025 Earnings Conference Call.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback